

CK2 conference 2010 in Cologne: outline of the scientific program

Session A: CK2 and tumour development

Khalil Ahmed, Minneapolis, USA

CK2 and protein B23 dynamics in relation to cell growth and apoptosis

Lorenzo A. Pinna, Padova, Italy

The master kinase CK2 and neoplasia: a tale of addiction

Janeen Trembley, Minneapolis, USA

Molecular targeting of CK2 in cancer therapy

Session B: CK2 and the circadian clock

Thomas Raabe, Würzburg, Germany

Cooperative function of CK2 and S6KII in regulation of the *Drosophila* circadian clock

Yoshiki Tsuchiya, Kyoto, Japan

The role of CK2 in the regulation of mammalian circadian rhythms

Session C: CK2 in developmental biology

Ashok Bidwai, Morgantown, USA

Roles of CK2 during Notch mediated neuronal patterning in *Drosophila*

Isabel Dominguez, Boston, USA

CK2's role in early development

Odile Filhol, Grenoble, France

Involvement of CK2 in mammary gland development

David Seldin, Boston, USA

Combined developmental roles of CK2 α and CK2 α'

Session D: Impact of CK2 on the cell cycle and on signal transduction pathways

Barbara Guerra, Odense, Denmark

CK2 and the eukaryotic cell cycle

Birgitte Olsen, Olaf-Georg Issinger, Odense, Denmark

Protein kinase CK2 in DNA damage/repair

David Litchfield, London, Canada

Convergence of CK2 with caspase signalling pathways

David Meek, Dundee, UK

The role of CK2 in regulating the p53 pathway

Yoshihiko Miyata, Kyoto, Japan

Control of cellular signal transduction systems by CK2

Heike Reebholz, New York, USA

The role of CK2 in regulating G-protein coupled receptor signaling

Session E: CK2 in yeasts and plants

Carmen Martinez, Barcelona, Spain

About the role of CK2 in plant signal transduction

Grazyna Muszynska, Warsaw, Poland

Role and variety of CK2 in *Zea mays*

Ryszard Szyszka, Lublin, Poland

Yeast CK2 - structure, substrates and regulation

Session F: Molecular and structural basis of CK2 activity and interactions

Matthias Montenarh, Homburg, Germany

New binding partners of protein kinase CK2

Karsten Niefind, Jennifer Raaf, Cologne, Germany

Structural determinants of CK2 function

Session G: Structure-based development of selective CK2-inhibitors

Kenna Anderes, San Diego, USA

Discovery and development of CX-4945, a potent small molecule inhibitor of CK2 for the treatment of cancer

Roberto Battistutta, Padova, Italy

Structural bases of CK2 inhibition

Maria Bretner, Warsaw, Poland

Design and synthesis of CK2 inhibitors

Claude Cochet, Grenoble, France

Targeting allosteric sites on CK2

Takayoshi Kinoshita, Osaka, Japan

A challenge in the application of SBDD of CK2 inhibitors supported by thermodynamic data and computat. analysis

Silvio Perea, Havana, Cuba

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoacceptor domain. Translational and clinical research